Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 234.98%.

  • Janux Therapeutics' EBITDA Margin rose 40046600.0% to 234.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 1051.64%, marking a year-over-year decrease of 6567400.0%. This contributed to the annual value of 637.48% for FY2024, which is 564900.0% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' EBITDA Margin is 234.98%, which was up 40046600.0% from 4239.64% recorded in Q3 2024.
  • In the past 5 years, Janux Therapeutics' EBITDA Margin registered a high of 79.25% during Q2 2024, and its lowest value of 4239.64% during Q3 2024.
  • In the last 5 years, Janux Therapeutics' EBITDA Margin had a median value of 831.01% in 2023 and averaged 1000.5%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -37754700bps in 2024, then surged by 40046600bps in 2025.
  • Janux Therapeutics' EBITDA Margin (Quarter) stood at 848.39% in 2021, then skyrocketed by 37bps to 538.59% in 2022, then increased by 25bps to 403.01% in 2023, then crashed by -952bps to 4239.64% in 2024, then surged by 94bps to 234.98% in 2025.
  • Its EBITDA Margin stands at 234.98% for Q3 2025, versus 4239.64% for Q3 2024 and 79.25% for Q2 2024.